Outlook Therapeutics Inc News - OTLKW

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference

ISELIN, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

ISELIN, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update

Reported positive, statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO...

Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference

Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, to participate in The Greatest...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

In NORSE TWO, ONS-5010 achieved statistically significant and clinically relevant primary (p = 0.0052) and key...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 &n...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 &nbs...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer

Experienced executive with a track-record of successful eye care product launchesAppointment reflects Outlook...

Outlook Therapeutics Announces Inclusion in the Russell 2000® Index

ISELIN, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late...

Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Topline readout of data from NORSE TWO targeted for calendar Q3 2021New Biologics License Application (BLA...

Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approve...

Drs. Mark Humayun and Firas Rahhal, leading retinal specialists and Advisors to Outlook Therapeutics, stress...

Quarterly Report (10-q)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

OTLKW News

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference

Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update

Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference

Current Report Filing (8-k)

Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Current Report Filing (8-k)

Current Report Filing (8-k)

Statement of Changes in Beneficial Ownership (4)

Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer

Outlook Therapeutics Announces Inclusion in the Russell 2000® Index

Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approve...

Quarterly Report (10-q)

Current Report Filing (8-k)

OTLKW Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW) News

Outlook Therapeutics Inc (OTLKW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

OTLKW News

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference

Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update

Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference

Current Report Filing (8-k)

Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Current Report Filing (8-k)

Current Report Filing (8-k)

Statement of Changes in Beneficial Ownership (4)

Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer

Outlook Therapeutics Announces Inclusion in the Russell 2000® Index

Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approve...

Quarterly Report (10-q)

Current Report Filing (8-k)

OTLKW Discussion

Your Recent History